Austrian Breast and Colorectal Cancer Study Group
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer
Filipits M, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C, Ferree S, Liu S, Cowens J, Gnant M, Dubsky P, Mlineritsch B, Singer C, Nielsen T, Rudas M, Greil R, Stöger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Austrian Breast and Colorectal Cancer Study Group. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res 2014; 20:1298-305.
Feb 11, 2014The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer
Feb 11, 2014Clin Cancer Res 2014; 20:1298-305
Filipits Martin, Bauernhofer Thomas, Hubalek Michael, Knauer Michael, Trapl Harald, Fesl Christian, Schaper Carl, Ferree Sean, Liu Shuzhen, Cowens J Wayne, Gnant Michael, Dubsky Peter, Mlineritsch Brigitte, Singer Christian F, Nielsen Torsten O, Rudas Margaretha, Greil Richard, Stöger Herbert, Jakesz Raimund, Bago-Horvath Zsuzsanna, Dietze Otto, Regitnig Peter, Gruber-Rossipal Christine, Müller-Holzner Elisabeth, Austrian Breast and Colorectal Cancer Study Group
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
Gnant M, Steger G, Balic M, Ressler S, Cowens J, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen T, Bartsch R, Fitzal F, Dubsky P, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2013; 25:339-45.
Dec 16, 2013Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
Dec 16, 2013Ann Oncol 2013; 25:339-45
Gnant M, Steger G, Balic M, Ressler S, Cowens J W, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen T O, Bartsch R, Fitzal F, Dubsky P, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer Michael, Singer C, Jakesz R, Austrian Breast and Colorectal Cancer Study Group